References of "Diaz-Curiel, M"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailMaintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.
Reginster, Jean-Yves ULg; Kaufman, J. M.; Goemaere, S. et al

in Osteoporosis International (2012), 23

In an open-label extension study, BMD increased continuously with strontium ranelate over 10 years in osteoporotic women (P < 0.01). Vertebral and nonvertebral fracture incidence was lower between 5 and ... [more ▼]

In an open-label extension study, BMD increased continuously with strontium ranelate over 10 years in osteoporotic women (P < 0.01). Vertebral and nonvertebral fracture incidence was lower between 5 and 10 years than in a matched placebo group over 5 years (P < 0.05). Strontium ranelate's antifracture efficacy appears to be maintained long term. INTRODUCTION: Strontium ranelate has proven efficacy against vertebral and nonvertebral fractures, including hip, over 5 years in postmenopausal osteoporosis. We explored long-term efficacy and safety of strontium ranelate over 10 years. METHODS: Postmenopausal osteoporotic women participating in the double-blind, placebo-controlled phase 3 studies SOTI and TROPOS to 5 years were invited to enter a 5-year open-label extension, during which they received strontium ranelate 2 g/day (n = 237, 10-year population). Bone mineral density (BMD) and fracture incidence were recorded, and FRAX(R) scores were calculated. The effect of strontium ranelate on fracture incidence was evaluated by comparison with a FRAX(R)-matched placebo group identified in the TROPOS placebo arm. RESULTS: The patients in the 10-year population had baseline characteristics comparable to those of the total SOTI/TROPOS population. Over 10 years, lumbar BMD increased continuously and significantly (P < 0.01 versus previous year) with 34.5 +/- 20.2% relative change from baseline to 10 years. The incidence of vertebral and nonvertebral fracture with strontium ranelate in the 10-year population in years 6 to 10 was comparable to the incidence between years 0 and 5, but was significantly lower than the incidence observed in the FRAX(R)-matched placebo group over 5 years (P < 0.05); relative risk reductions for vertebral and nonvertebral fractures were 35% and 38%, respectively. Strontium ranelate was safe and well tolerated over 10 years. CONCLUSIONS: Long-term treatment with strontium ranelate is associated with sustained increases in BMD over 10 years, with a good safety profile. Our results also support the maintenance of antifracture efficacy over 10 years with strontium ranelate. [less ▲]

Detailed reference viewed: 20 (8 ULg)
Full Text
Peer Reviewed
See detailVertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover.
Collette, Julien ULg; Bruyère, Olivier ULg; Kaufman, J. M. et al

in Osteoporosis International (2010), 21(2), 233-41

Osteoporotic post-menopausal women patients in two randomised trials comparing the anti-fracture efficacy of strontium ranelate with placebo were separated into tertiles according to their baseline levels ... [more ▼]

Osteoporotic post-menopausal women patients in two randomised trials comparing the anti-fracture efficacy of strontium ranelate with placebo were separated into tertiles according to their baseline levels of biochemical markers of bone formation and resorption. The vertebral anti-fracture efficacy of strontium ranelate was shown to be independent of baseline bone turnover levels. INTRODUCTION: Bone turnover (BTO) levels vary among women at risk of osteoporotic fracture. Strontium ranelate is an anti-osteoporotic treatment increasing bone formation and reducing bone resorption. It was hypothesised that its anti-fracture efficacy would be independent of baseline BTO levels. METHODS: Post-menopausal women with osteoporosis from two pooled studies were stratified in tertiles according to baseline levels of two BTO markers: bone-specific alkaline phosphatase (b-ALP, n = 4995) and serum C-telopeptide cross-links (sCTX, n = 4891). Vertebral fracture risk was assessed over 3 years with strontium ranelate 2 g/day or placebo. RESULTS: In the placebo group, relative risk of vertebral fractures increased with BTO tertiles by 32% and 24% for patients in the highest tertile for b-ALP and CTX, respectively, compared to those in the lowest tertile. In the strontium ranelate group, incidences of vertebral fracture did not differ significantly across BTO tertiles. Significant reductions in vertebral fractures with strontium ranelate were seen in all tertiles of both markers, with relative risk reductions of 31% to 47% relative to placebo. Risk reduction did not differ among tertiles (b-ALP: p = 0.513; sCTX: p = 0.290). CONCLUSION: The vertebral anti-fracture efficacy of strontium ranelate was independent of baseline BTO levels. Strontium ranelate offers clinical benefits to women across a wide range of metabolic states. [less ▲]

Detailed reference viewed: 60 (22 ULg)
Full Text
Peer Reviewed
See detailEffects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
Meunier, Pierre; Roux, C.; Ortolani, S. et al

in Osteoporosis International (2009), 20

Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33 ... [more ▼]

Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33% over 4 years, confirming the role of strontium ranelate as an effective long-term treatment in osteoporosis. INTRODUCTION: Osteoporotic vertebral fractures are associated with increased mortality, morbidity, and loss of quality-of-life (QoL). Strontium ranelate (2 g/day) was shown to prevent bone loss, increase bone strength, and reduce vertebral and peripheral fractures. The preplanned aim of this study was to evaluate long-term efficacy and safety of strontium ranelate. METHODS: A total of 1,649 postmenopausal osteoporotic women were randomized to strontium ranelate or placebo for 4 years, followed by a 1-year treatment-switch period for half of the patients. Primary efficacy criterion was incidence of patients with new vertebral fractures over 4 years. Lumbar bone mineral density (BMD) and QoL were also evaluated. RESULTS: Over 4 years, risk of vertebral fracture was reduced by 33% with strontium ranelate (risk reduction = 0.67, p < 0.001). Among patients with two or more prevalent vertebral fractures, risk reduction was 36% (p < 0.001). QoL, assessed by the QUALIOST(R), was significantly better (p = 0.025), and patients without back pain were greater (p = 0.005) with strontium ranelate than placebo over 4 years. Lumbar BMD increased over 5 years in patients who continued with strontium ranelate, while it decreased in patients who switched to placebo. Emergent adverse events were similar between groups. CONCLUSION: In this 4- and 5-year study, strontium ranelate is an effective and safe treatment for long-term treatment of osteoporosis in postmenopausal women. [less ▲]

Detailed reference viewed: 48 (11 ULg)
Full Text
Peer Reviewed
See detailRelationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate
Bruyère, Olivier ULg; Roux, C.; Detilleux, Johann ULg et al

in Journal of Clinical Endocrinology and Metabolism (2007), 92(8), 3076-3081

Objective: Our objective was to analyze the relationship between bone mineral density (BMD) changes and fracture incidence during 3-yr treatment with strontium ranelate. Patients: Women from the strontium ... [more ▼]

Objective: Our objective was to analyze the relationship between bone mineral density (BMD) changes and fracture incidence during 3-yr treatment with strontium ranelate. Patients: Women from the strontium ranelate arm of the Spinal Osteoporosis Therapeutic Intervention study and the TReatment Of Peripheral OSteoporosis study were evaluated. Outcome Measures: The outcome measures included BMD at the lumbar spine, femoral neck, and total proximal femur assessed at baseline and after a follow-up of 1 and 3 yr; semiquantitative visual assessment of vertebral fractures; and nonvertebral fractures based on written documentation. Results: After 3 yr of strontium ranelate treatment, each percentage point increase in femoral neck and total proximal femur BMD was associated with a 3%(95% adjusted confidence interval, 1-5%) and2% (1-4%) reduction in risk of a new vertebral fracture, respectively. The 3- yr changes in femoral neck and total proximal femur BMD explained 76% and 74%, respectively, of the reduction in vertebral fractures observed during the treatment. Three-year changes in spine BMD were not statistically associated with the incidence of new vertebral fracture (P = 0.10). No significant associations were found between 3- yr changes in BMD and incidence of new nonvertebral fractures, but a trend was found for femoral neck BMD (P = 0.09) and for total proximal femur BMD (P = 0.07). An increase in femoral neck BMD after 1 yr was significantly associated with the reduction in incidence of new vertebral fractures observed after 3 yr (P = 0.04). Conclusion: During 3-yr strontium ranelate treatment, an increase in femoral neck BMD was associated with a proportional reduction in vertebral fracture incidence. [less ▲]

Detailed reference viewed: 48 (21 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fracture in patients with osteopenia
Seeman, E.; Sawicki, A.; Reginster, Jean-Yves ULg et al

in Osteoporosis International (2006, June), 17(Suppl.2), 85

Detailed reference viewed: 5 (1 ULg)
See detailStrontium ranelate reduces the risk of vertebral fracture in patients with osteopenia
Seeman, E.; Sawicki, A.; Reginster, Jean-Yves ULg et al

in Osteoporosis International (2006, May), 17(Suppl. 2), 209

Detailed reference viewed: 9 (4 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fracture in patients with osteopenia
Seeman, E.; Sawicki, A.; Reginster, Jean-Yves ULg et al

in Osteoporosis International (2006, March), 17(Suppl.1), 50

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailPatients at high risk of hip fracture benefit from treatment with strontium ranelate
Rizzoli, René; Reginster, Jean-Yves ULg; Diaz-Curiel, M. et al

in Osteoporosis International (2004, May), 15(Suppl.1), 18

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fractures in postmenopausal women with osteopenia
Sawicki, A; Reginster, Jean-Yves ULg; Roux, C et al

in Osteoporosis International (2004), 15(S1), 119-120

Detailed reference viewed: 8 (4 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fractures in postmenopausal women with osteopenia
Sawicki, A.; Reginster, Jean-Yves ULg; Roux, C. et al

in Calcified Tissue International (2004), 74(S1), 84

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailPatients at high risk of hip fracture benefit from treatment with strontium ranelate
Rizzoli, R.; Reginster, Jean-Yves ULg; Diaz-Curiel, M. et al

in Calcified Tissue International (2004), 74(S1), 83-84

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailEarly effect of strontium ranelate on clinical vertebral fractures in women with postmenopausal osteoporosis
Meunier, P. J.; Marquis, P.; Lemmel, E. M. et al

in BONE (2003), 32(S7), 222

Detailed reference viewed: 10 (7 ULg)